[go: up one dir, main page]

RU2010149495A - Новые адъювантные композиции - Google Patents

Новые адъювантные композиции Download PDF

Info

Publication number
RU2010149495A
RU2010149495A RU2010149495/15A RU2010149495A RU2010149495A RU 2010149495 A RU2010149495 A RU 2010149495A RU 2010149495/15 A RU2010149495/15 A RU 2010149495/15A RU 2010149495 A RU2010149495 A RU 2010149495A RU 2010149495 A RU2010149495 A RU 2010149495A
Authority
RU
Russia
Prior art keywords
composition
composition according
animal
item
add
Prior art date
Application number
RU2010149495/15A
Other languages
English (en)
Other versions
RU2510280C2 (ru
Inventor
Седо Мартин БАГИ (US)
Седо Мартин БАГИ
Тедд Алан ЧАЙЛДЕРС (US)
Тедд Алан ЧАЙЛДЕРС
Пол Джозеф ДОМИНОУСКИ (US)
Пол Джозеф ДОМИНОУСКИ
Ричард Ли КРЕБС (US)
Ричард Ли КРЕБС
Рамасами Маннар МАННАН (US)
Рамасами Маннар МАННАН
Мэри Кэтрин ОЛСЕН (US)
Мэри Кэтрин ОЛСЕН
Джеймс Ричард ТОМПСОН (US)
Джеймс Ричард ТОМПСОН
Рисини Даммика УИРАТНА (CA)
Рисини Даммика УИРАТНА
Роберт Джон Младший ЯНСИ (US)
Роберт Джон Младший ЯНСИ
Шучен ЧЗАН (US)
Шучен ЧЗАН
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. (US), Пфайзер Инк. filed Critical Пфайзер Инк. (US)
Publication of RU2010149495A publication Critical patent/RU2010149495A/ru
Application granted granted Critical
Publication of RU2510280C2 publication Critical patent/RU2510280C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

1. Иммуногенная композиция, содержащая адъювантную композицию и иммунологически эффективное количество антигенного компонента, где адъювантная композиция содержит сапонин, стерол, четвертичное аммониевое соединение, полимер и возможно стимулятор Th2. ! 2. Способ приготовления иммуногенной композиции по п.1, при котором: ! а) готовят композицию антигенного компонента в буфере; ! б) добавляют сапонин к композиции со стадии (а); ! в) добавляют стерол к композиции со стадии (б); ! г) добавляют четвертичное аммониевое соединение к композиции со стадии (в); ! д) добавляют полимер к композиции со стадии (г); и ! е) возможно добавляют стимулятор Th2 к композиции со стадии (д). ! 3. Вакцинная композиция, содержащая адъювантную композицию и терапевтически эффективное количество антигенного компонента, где адъювантная композиция содержит сапонин, стерол, четвертичное аммониевое соединение, полимер и возможно стимулятор Th2. ! 4. Композиция по п.1 или 3, где сапонин представляет собой Quil A или его очищенную фракцию, стерол представляет собой холестерин, четвертичное аммониевое соединение представляет собой диметилдиоктадециламмоний бромид (DDA), полимер представляет собой полиакриловую кислоту, и стимулятор Th2 представляет собой гликолипид. ! 5. Композиция по любому из пп.1 или 3, дополнительно содержащая масло. ! 6. Способ приготовления вакцинной композиции по п.3, при котором: ! а) готовят композицию антигенного компонента в буфере; ! б) добавляют сапонин к композиции со стадии (а); ! в) добавляют стерол к композиции со стадии (б); ! г) добавляют четвертичное аммониевое соединение к композиции со стадии (в); ! д) добавляют полимер к композиции

Claims (23)

1. Иммуногенная композиция, содержащая адъювантную композицию и иммунологически эффективное количество антигенного компонента, где адъювантная композиция содержит сапонин, стерол, четвертичное аммониевое соединение, полимер и возможно стимулятор Th2.
2. Способ приготовления иммуногенной композиции по п.1, при котором:
а) готовят композицию антигенного компонента в буфере;
б) добавляют сапонин к композиции со стадии (а);
в) добавляют стерол к композиции со стадии (б);
г) добавляют четвертичное аммониевое соединение к композиции со стадии (в);
д) добавляют полимер к композиции со стадии (г); и
е) возможно добавляют стимулятор Th2 к композиции со стадии (д).
3. Вакцинная композиция, содержащая адъювантную композицию и терапевтически эффективное количество антигенного компонента, где адъювантная композиция содержит сапонин, стерол, четвертичное аммониевое соединение, полимер и возможно стимулятор Th2.
4. Композиция по п.1 или 3, где сапонин представляет собой Quil A или его очищенную фракцию, стерол представляет собой холестерин, четвертичное аммониевое соединение представляет собой диметилдиоктадециламмоний бромид (DDA), полимер представляет собой полиакриловую кислоту, и стимулятор Th2 представляет собой гликолипид.
5. Композиция по любому из пп.1 или 3, дополнительно содержащая масло.
6. Способ приготовления вакцинной композиции по п.3, при котором:
а) готовят композицию антигенного компонента в буфере;
б) добавляют сапонин к композиции со стадии (а);
в) добавляют стерол к композиции со стадии (б);
г) добавляют четвертичное аммониевое соединение к композиции со стадии (в);
д) добавляют полимер к композиции со стадии (г); и
е) возможно добавляют стимулятор Th2 к композиции со стадии (д).
7. Способ по любому из п.2 или 6, где сапонин представляет собой Quil А или его очищенную фракцию, стерол представляет собой холестерин, четвертичное аммониевое соединение представляет собой диметилдиоктадециламмоний бромид (DDA), полимер представляет собой полиакриловую кислоту, и стимулятор Th2 представляет собой гликолипид.
8. Способ по п.2 или 6, при котором дополнительно осуществляют стадию добавления композиции со стадии (д) к масляной фазе.
9. Способ по п.2 или 6, при котором дополнительно осуществляют стадию добавления композиции со стадии (е) к масляной фазе.
10. Способ по п.2 или 6, при котором дополнительно осуществляют стадию, включающую микрофлюидизацию композиции со стадии (г).
11. Композиция по п.1 или п.3, где стимулятор Th2 представляет собой N-(2-дезокси-2-L-лейциламино-β-D-глюкопиранозил)-N-октадецилдодеканамида ацетат.
12. Композиция по любому из пп.1 или 3, где антигенный компонент включает:
(а) вирус лейкемии кошек;
(б) бактерин штамма J-5 Escherichia coli;
(в) вирус диареи крупного рогатого скота (BVDV);
(г) BVDV тип 1 (BVDV-1) и BVDV тип 2 (BVDV-2);
(д) Mycoplasma hyopneumonia (М.hyopneumonia);
(е) вирус кошачьего гриппа (FIV);
(ж) антиген рака;
(з) коронавирус собак (CCV);
(и) ротавирус крупного рогатого скота; или
(к) вирус собачьего гриппа (CIV).
13. Вакцинная композиция по п.12 (а) для лечения животного семейства кошачьих от инфекции, вызванной вирусом лейкемии кошек.
14. Вакцинная композиция по п.12 (б) для лечения животного, являющегося представителем крупного рогатого скота, от инфекции, вызванной Escherichia coli.
15. Вакцинная композиция по п.12 (в) или 12 (г) для лечения животного, являющегося представителем крупного рогатого скота, от инфекции, вызванной вирусом диареи крупного рогатого скота (BVDV).
16. Вакцинная композиция по п.12 (д) для лечения животного семейства свиней от инфекции, вызванной М.hyopneumonia.
17. Вакцинная композиция по п.12 (е) для лечения животного семейства кошачьих от инфекции, вызванной вирусом кошачьего гриппа (FIV).
18. Вакцинная композиция по п.12 (ж) для лечения субъекта от рака.
19. Вакцинная композиция по п.12 (з) для лечения животного семейства собачьих от инфекции, вызванной коронавирусом собак (CCV).
20. Вакцинная композиция по п.12 (и) для лечения животного, являющегося представителем крупного рогатого скота, от инфекции, вызванной ротавирусом крупного рогатого скота.
21. Вакцинная композиция по п.12 (к) для лечения животного семейства собачьих от инфекции, вызванной вирусом собачьего гриппа (CIV).
22. Вакцина против кокцидиоза птиц для введения in ovo, содержащая:
(а) адъювант, содержащий Quil А или его очищенную фракцию, включая QS21, холестерин, CARBOPOL, DDA и R1005; и
(б) антиген простейшего, выбранный из (1) одного или более чем одного рекомбинантно экспрессированного белка, (2) одного или более чем одного белка или другой макромолекулы, выделенной из указанного простейшего обычным способом, и (3) экстрактов целых клеток или препаратов указанного простейшего.
23. Способ дифференцировки животного, инфицированного BVDV в природе, от животного, вакцинированного вакцинной композицией по п.12 (в) или 12 (г), при котором получают образец у тестируемого животного и измеряют уровни белка Е2 и белков NS2/3 в указанном образце, где отсутствие белков NS2/3 указывает на то, что животное было вакцинировано указанной вакцинной композицией.
RU2010149495/15A 2008-06-27 2009-06-24 Новые адъювантные композиции RU2510280C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7623208P 2008-06-27 2008-06-27
US61/076,232 2008-06-27
US21455709P 2009-04-24 2009-04-24
US61/214,557 2009-04-24
PCT/IB2009/052724 WO2009156960A2 (en) 2008-06-27 2009-06-24 Novel adjuvant compositions

Publications (2)

Publication Number Publication Date
RU2010149495A true RU2010149495A (ru) 2012-08-10
RU2510280C2 RU2510280C2 (ru) 2014-03-27

Family

ID=41445049

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010149495/15A RU2510280C2 (ru) 2008-06-27 2009-06-24 Новые адъювантные композиции

Country Status (29)

Country Link
US (6) US8580280B2 (ru)
EP (4) EP3725328A3 (ru)
JP (5) JP5659332B2 (ru)
KR (1) KR101333852B1 (ru)
CN (4) CN104758929B (ru)
AR (1) AR072378A1 (ru)
AU (1) AU2009263759B2 (ru)
BR (2) BR122021025097B1 (ru)
CA (3) CA2960846C (ru)
CL (1) CL2010001360A1 (ru)
CO (1) CO6331297A2 (ru)
CY (2) CY1117650T1 (ru)
DK (2) DK2310046T3 (ru)
ES (2) ES2569907T3 (ru)
HR (1) HRP20190876T1 (ru)
HU (2) HUE043493T2 (ru)
LT (1) LT3056214T (ru)
ME (1) ME01199B (ru)
MX (6) MX344311B (ru)
NZ (5) NZ621834A (ru)
PH (2) PH12014501836A1 (ru)
PL (2) PL2310046T3 (ru)
PT (1) PT3056214T (ru)
RU (1) RU2510280C2 (ru)
SI (2) SI2310046T1 (ru)
TW (4) TWI614027B (ru)
UY (1) UY31942A (ru)
WO (1) WO2009156960A2 (ru)
ZA (1) ZA201007835B (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PE20110998A1 (es) * 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
BR112012002963A2 (pt) * 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
JP2011251963A (ja) 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
PE20140576A1 (es) * 2011-06-10 2014-05-24 Novartis Ag Vacunas bovinas y metodos
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
CA3170184A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
CN108379571A (zh) 2012-12-28 2018-08-10 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
CN103127495B (zh) * 2013-01-28 2015-04-08 重庆市畜牧科学院 二联灭活苗的制剂及其制备方法
US20160199482A1 (en) * 2013-09-05 2016-07-14 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
CN105764525A (zh) 2013-09-19 2016-07-13 硕腾服务有限责任公司 油基佐剂
AU2014337452A1 (en) 2013-10-17 2016-04-21 Zoetis Services Llc Methods and compositions for treatment of S. equi infection
MX390596B (es) * 2013-11-26 2025-03-19 Zoetis Services Llc Procedimientos y composicion para la induccion de respuesta inmunitaria.
MX388527B (es) * 2014-11-26 2025-03-20 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
PL3244920T3 (pl) * 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
US9636397B2 (en) * 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
CN104771754B (zh) * 2015-04-02 2018-02-13 武汉科前生物股份有限公司 一种猪圆环病毒2型灭活疫苗水性佐剂及应用
CN106267183B (zh) * 2015-06-09 2023-02-28 普莱柯生物工程股份有限公司 含有佐剂的活疫苗组合物及其制备方法和应用
CN106344920B (zh) * 2015-07-16 2020-11-27 普莱柯生物工程股份有限公司 一种疫苗用佐剂及其应用
BR112018001318B1 (pt) * 2015-07-20 2023-11-14 Zoetis Services Llc Lipossoma livre de saponina, formulação adjuvante, composição de vacina, uso terapêutico de um componente antigênico e da formulação adjuvante e método para preparar o referido lipossoma
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
WO2017068482A1 (en) * 2015-10-19 2017-04-27 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
KR20210068602A (ko) 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US10092604B1 (en) * 2017-12-21 2018-10-09 Bioceuticals Pte. Ltd. Methods for treatment of skin infectious diseases using microorganisms
JP7497293B2 (ja) 2018-03-16 2024-06-10 ゾエティス・サービシーズ・エルエルシー インターロイキン－３１に対するペプチドワクチン
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
US11046734B2 (en) 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
CN114514238A (zh) * 2019-07-12 2022-05-17 研究发展基金会 埃立克体疫苗和免疫原性组合物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2022016382A (es) * 2020-06-19 2023-01-30 Kimberly Clark Co Extractos que contienen saponina preparados a partir de hesperaloe utiles en el tratamiento de animales no humanos.
BR112022025449A2 (pt) * 2020-06-19 2023-01-24 Kimberly Clark Co Composição imunológica útil para induzir a produção de anticorpos para um antígeno em um animal não humano, e, uso da mesma
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114848807A (zh) * 2021-02-04 2022-08-05 洛阳赛威生物科技有限公司 一种蜂胶佐剂组合物、及其制备方法以及应用
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants
EP4665313A1 (fr) * 2023-02-16 2025-12-24 Vaxinano Composition vaccinale comprenant un systeme de delivrance d'une bacterie entiere inactivee via des nanoparticules polysaccharidiques cationiques sans adjuvant
WO2025006564A1 (en) 2023-06-26 2025-01-02 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN121360223A (zh) * 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ATE60999T1 (de) 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
CA2127466A1 (en) * 1992-01-06 1993-07-22 Keith Haffer Feline leukemia virus vaccines
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
CN1254292A (zh) * 1997-04-30 2000-05-24 梅里厄奥拉瓦克斯公司 通过膈下内吸收途径使用的抗螺杆菌疫苗组合物,以及粘膜/非肠道联用免疫方法
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
AU745183B2 (en) * 1997-10-20 2002-03-14 Bayer Corporation Neospora vaccines
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
ATE305507T1 (de) 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
ES2257068T3 (es) 1998-08-10 2006-07-16 Antigenics Inc. Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1350262B8 (en) 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2004527524A (ja) 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CN1526016A (zh) 2001-05-21 2004-09-01 �����ɷ� 稳定核酸的方法
JP2005509591A (ja) 2001-06-15 2005-04-14 リバファーム・インコーポレイテッド ヌクレオシドワクチンアジュバント
YU102203A (sh) * 2001-07-02 2006-05-25 Pfizer Products Inc. Vakcinacija sa jednokratnom dozom mycoplasma hyopneumoniae
EP1521592A2 (en) * 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003025119A2 (en) 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
US20030133988A1 (en) 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
PL368826A1 (en) 2001-08-28 2005-04-04 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US7514415B2 (en) 2002-08-01 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003030934A2 (en) 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP2005516897A (ja) 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP2005517718A (ja) 2002-02-19 2005-06-16 シンセリカ・コーポレイション 免疫応答および輸送の代替抗体による調整のための組成物および方法
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
EP1497424A1 (en) 2002-04-22 2005-01-19 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2487452A1 (en) 2002-05-28 2003-12-04 Robinson Ramirez-Pineda A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
NZ539746A (en) 2002-11-05 2008-03-28 James Hardie Int Finance Bv Method and apparatus for producing calcium silicate hydrate
CN1835767A (zh) * 2003-01-29 2006-09-20 辉瑞产品公司 对抗支气管败血性博德特氏杆菌的犬疫苗
AU2003900767A0 (en) * 2003-02-21 2003-03-13 St Vincent's Hospital Sydney Limited Idiotypic vaccine
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
CA2521051C (en) 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
DK1742659T3 (da) 2004-04-05 2013-06-03 Zoetis P Llc Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
NZ554142A (en) * 2004-10-06 2009-12-24 Agri Biotech Pty Ltd Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
GB0426481D0 (en) * 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
CA2604488A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
BRPI0616328A2 (pt) * 2005-10-07 2011-06-14 Pfizer Prod Inc vacinas e mÉtodos para tratar influenza canino
EP1954252B1 (en) * 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
ME00045B (me) * 2006-01-26 2010-10-10 Zoetis Services Llc Nove kompozicije glikolipidnog adjuvansa
RU2008134426A (ru) * 2006-01-26 2010-03-10 ЭйчИкс ДИАГНОСТИКС, ИНК. (US) Моноклональные антитела, связывающиеся с вирусом птичьего гриппа
US20080187546A1 (en) * 2006-12-15 2008-08-07 Wasmoen Terri L Method for Replicating Influenza Virus in Culture
US8193246B2 (en) * 2006-12-19 2012-06-05 Marina Biotech, Inc. Lipids and lipid assemblies comprising transfection enhancer elements
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
BRPI1005919B1 (pt) 2009-02-27 2021-06-22 Toray Industries, Inc Composição imunogênica
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Also Published As

Publication number Publication date
US10940202B2 (en) 2021-03-09
TW201540311A (zh) 2015-11-01
CL2010001360A1 (es) 2011-04-08
US20090324641A1 (en) 2009-12-31
AU2009263759B2 (en) 2013-06-06
MX368220B (es) 2019-09-24
CO6331297A2 (es) 2011-10-20
JP5659332B2 (ja) 2015-01-28
CA2960734C (en) 2021-08-24
US11896666B2 (en) 2024-02-13
PL3056214T3 (pl) 2019-09-30
JP2014111619A (ja) 2014-06-19
TWI614027B (zh) 2018-02-11
AU2009263759A1 (en) 2009-12-30
HUE043493T2 (hu) 2019-08-28
TWI622401B (zh) 2018-05-01
JP6038211B2 (ja) 2016-12-07
TW201544121A (zh) 2015-12-01
HUE028921T2 (en) 2017-01-30
SI2310046T1 (sl) 2016-05-31
NZ589079A (en) 2012-11-30
HRP20190876T1 (hr) 2019-07-12
BRPI0913954A2 (pt) 2021-04-06
EP2310046B1 (en) 2016-03-09
HK1201445A1 (en) 2015-09-04
BR122021025097B1 (pt) 2022-07-26
WO2009156960A9 (en) 2010-09-30
CN104758929A (zh) 2015-07-08
CY1121789T1 (el) 2020-07-31
TWI513464B (zh) 2015-12-21
UY31942A (es) 2010-01-29
US10238736B2 (en) 2019-03-26
KR101333852B1 (ko) 2013-11-27
JP2014111620A (ja) 2014-06-19
US8580280B2 (en) 2013-11-12
JP2011525911A (ja) 2011-09-29
JP2015143244A (ja) 2015-08-06
US20240358825A1 (en) 2024-10-31
EP3725328A3 (en) 2020-12-23
JP2017061484A (ja) 2017-03-30
EP3056214B1 (en) 2019-04-03
CA2960846C (en) 2020-08-25
AR072378A1 (es) 2010-08-25
CN104001170A (zh) 2014-08-27
CN102076358A (zh) 2011-05-25
CN104001169A (zh) 2014-08-27
PH12014501836A1 (en) 2016-03-07
SI3056214T1 (sl) 2019-06-28
BRPI0913954B1 (pt) 2022-04-05
ME01199B (me) 2013-03-20
MX349720B (es) 2017-08-09
US20210338810A1 (en) 2021-11-04
JP6294938B2 (ja) 2018-03-14
US20140056940A1 (en) 2014-02-27
JP5824538B2 (ja) 2015-11-25
CA2960734A1 (en) 2009-12-30
CN104758929B (zh) 2018-05-25
US20170304434A1 (en) 2017-10-26
NZ709547A (en) 2017-01-27
TWI622400B (zh) 2018-05-01
LT3056214T (lt) 2019-06-10
MX2010014026A (es) 2011-02-15
RU2510280C2 (ru) 2014-03-27
CN104001170B (zh) 2016-08-24
NZ621834A (en) 2015-10-30
EP2310046A2 (en) 2011-04-20
US12521433B2 (en) 2026-01-13
CA2960846A1 (en) 2009-12-30
HK1211870A1 (en) 2016-06-03
WO2009156960A2 (en) 2009-12-30
MX344311B (es) 2016-12-13
CY1117650T1 (el) 2017-04-26
DK3056214T3 (da) 2019-05-13
EP3725328A2 (en) 2020-10-21
ES2569907T3 (es) 2016-05-13
PL2310046T3 (pl) 2016-09-30
DK2310046T3 (da) 2016-04-25
TW201014601A (en) 2010-04-16
CA2723786C (en) 2020-04-28
NZ602945A (en) 2014-05-30
MX2019011253A (es) 2019-11-01
CA2723786A1 (en) 2009-12-30
US9662385B2 (en) 2017-05-30
PH12014501835A1 (en) 2016-03-07
EP3056214A1 (en) 2016-08-17
CN104001169B (zh) 2016-03-23
US20190008953A1 (en) 2019-01-10
KR20110010817A (ko) 2011-02-07
HK1201444A1 (zh) 2015-09-04
WO2009156960A3 (en) 2010-06-17
TW201544122A (zh) 2015-12-01
EP3552625A1 (en) 2019-10-16
MX375202B (es) 2025-03-06
NZ727616A (en) 2018-06-29
JP5882370B2 (ja) 2016-03-09
ZA201007835B (en) 2012-01-25
PT3056214T (pt) 2019-06-12
CN102076358B (zh) 2016-08-17
ES2728949T3 (es) 2019-10-29

Similar Documents

Publication Publication Date Title
RU2010149495A (ru) Новые адъювантные композиции
BR112015012711B1 (pt) Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma
EA200301324A1 (ru) Вакцина mycoplasma bovis и способы сокращения пневмонии у животных
US5807551A (en) Method to provide artificial passive immunity in birds
ES2808673T3 (es) Composición inmunogénica que comprende antígenos de micoplasma
KR20110081233A (ko) 어류의 스쿠티카증 예방 치료 백신
BR112015024882B1 (pt) Composição, vacina contra carrapatos rhipicephalus, métodos para a preparação de uma composição e de uma vacina contra carrapatos rhipicephalus, proteína bm86 ou homólogo da mesma e uma proteína subolesina ou homólogo da mesma, uso de proteína bm86 ou homólogo da mesma e de uma proteína subolesina ou homólogo da mesma, e, kit de partes
Mazija et al. Immunogenicity and safety of Queensland V4 and Ulster 2C strains of Newcastle disease virus given to maternally immune, newly hatched chickens by nebulization
CN110507819B (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
Umali et al. Antibody response and protective immunity of chickens vaccinated with booster dose of recombinant oil-adjuvanted Leucocytozoon caulleryi subunit vaccine
JP2913229B2 (ja) 油性アジュバントワクチン製剤
US4328208A (en) Vaccine against chlamydous infections of farm animals
Araghi et al. Evaluation of immunogenicity of Clostridium perfringens type B toxoid and inactivated FMD (O) virus with adjuvant (ISA70-MF59)
Muhammad et al. Effect of different adjuvants used in Foot and Mouth Disease virus vaccine on antibody response of buffalo calves.
US20170290895A1 (en) Heartworm vaccine, methods and uses thereof
JP2000219637A (ja) エリシペロスリクス・ルシオパシエ抗原及びワクチン組成物
Wambura et al. Protective immune response of chickens to oral vaccination with thermostable live Fowlpox virus vaccine (strain TPV-1) coated on oiled rice
RU1615919C (ru) Вакцина против вирусного энтерита, ботулизма и чумы плотоядных, способ ее изготовления и способ профилактики этих заболеваний
Singh et al. Diseases of Animals: Diagnosis and Management
Jabeen et al. Preliminary Assessment of Newly Developed Escherichia coli Mastitis Vaccines in Laboratory Animals: Promising Results
Shah et al. Volume 2 Animal Health Perspectives
Curtis Examination of the impact of bovine anaplasmosis on dairy and beef operations, and evaluation of control with antimicrobial chemosterilization or vaccination with an ear-implant delivery platform
RU2554055C1 (ru) Способ иммунизации животных против бруцеллеза
El-Bagoury et al. Comparative study on live attenuated and inactivated chicken anemia virus vaccines
JPH0681731B2 (ja) 動物用ワクチン

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20150617

TC4A Change in inventorship

Effective date: 20151026

PC41 Official registration of the transfer of exclusive right

Effective date: 20151120

PD4A Correction of name of patent owner